As a multi-targeted anti-angiogenic receptor tyrosine kinase (RTK) inhibitor sunitinib (SUN) has been established for renal cancer and gastrointestinal stromal tumors. This evidence concerns the gene NTRK1 and gastrointestinal stromal tumor.